Close Menu

Arch Venture Partners

The firm, cofounded by several Harvard University researchers, is commercializing a single-cell spatial transcriptomics technology called MERFISH. 

The new company hopes to turn recombinant adeno-associated virus-based gene editing, which has minimal off-target effects, into new therapies.

The new firm will be based in the Boston area and is co-founded by MD Anderson Professor Raghu Kalluri and Broad Institute Director Eric Lander.

Leroy Hood called the bill short-sighted and said that over the long-term it could potentially reduce the attractiveness of starting up companies in the Seattle area.

The newly formed Decode Genetics Ehf will continue all of Decode's human genetics operations and brand products and services. Meantime, the publicly traded entity known as Decode Genetics expects to be liquidated.

Saga Investments has financial backing from Arch Venture Partners and Polaris Venture Partners, both of which had previously invested in Decode.

Lycera, which is developing drugs for autoimmune diseases, will use the cash to advance through Phase II proof-of-concept studies a drug based on University of Michigan research, and into Phase I trials a second candidate based on research conducted at New York University.

The deal brings to six the number of academic institutions from which Fate has licensed IP related to using small molecules to induce pluripotency in stem cells for therapeutic effect, drug discovery, and matched cell-replacement therapies.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.